Introduction {#Sec1}
============

The standard of care for rectal cancer (RC) patients is total mesorectal excision (TME) with or without preoperative therapy depending on clinical stage. For patients with locally advanced RC, preoperative treatment consists of chemoradiation therapy (CRT) intended to reduce local recurrence rates and to facilitate radical surgery by inducing tumor regression and possible downstaging \[[@CR1], [@CR2]\]. Significant tumor and nodal downstaging is reported in patients treated with CRT and depends on factors such as tumor type, clinical stage, and interval between radiation therapy and surgery \[[@CR3]--[@CR7]\]. Downstaging is associated with an improved prognosis, especially in 8--24% of patients with a pathological complete response (pCR) \[[@CR1], [@CR6], [@CR8], [@CR9]\]. The TNM staging system \[[@CR10], [@CR11]\] recommends adding the prefix "y" to the TNM stage after preoperative therapy to indicate that a tumor may have undergone treatment-induced response or regression.

Especially in Western European countries, patients may also undergo preoperative short-course radiation therapy (SC-RT) followed by immediate surgery \[[@CR12]--[@CR15]\]. Randomized trials show a small downstaging effect in these patients \[[@CR13], [@CR14]\], and according to the definitions of the TNM classification, the "y" prefix should be added. However, downstaging does not occur after SC-RT if the overall treatment time (i.e., interval between start of radiation therapy and rectal resection) does not exceed 10 days \[[@CR16]\]. The prognostic significance of ypTNM stage for patients in these groups (with vs. without possible downstaging) is still unclear. Due to the differences in levels of downstaging between groups of patients treated either with preoperative SC-RT followed by immediate surgery or with CRT \[[@CR17]\], it may be hypothesized that the prognostic implications of the "y" prefix depend on the type of preoperative therapy received, which limits the prognostic value of staging.

The purpose of this study is therefore to investigate on a population level whether stage-specific overall survival is different between patients treated with either SC-RT followed by surgery within 10 days after start of treatment (no tumor regression expected; ypTNM by definition, but may reflect pTNM) or preoperative long-course CRT (intended to induce tumor regression; ypTNM) and to compare results with patients who underwent surgery only (pTNM).

Patients and methods {#Sec2}
====================

Study design and patient selection {#Sec3}
----------------------------------

A population-based approach was employed using data from the nationwide Netherlands Cancer Registry (NCR). This institute collects data on all newly diagnosed cancer patients in the Netherlands since 1989. The registration is primarily based on notification by the Dutch national digital pathology registry (PALGA). Patient and clinicopathological data are routinely collected from medical records by specially trained data managers. Tumor location and histology is registered according to the ICD-O3 classification. Follow-up data and vital status are retrieved by linkage to the nationwide population registries network.

Patients with RC diagnosed between January 2008 and December 2014 who underwent a surgical resection were selected from the NCR. Clinicopathological characteristics and overall survival (including TNM stage-specific survival) were compared between patients treated with surgery only, preoperative SC-RT with an overall treatment time that did not exceed 10 days, and preoperative long-course CRT. The maximum interval of 10 days between start of SC-RT and surgery was chosen, since tumor regression is not likely to occur within this timeframe \[[@CR16]\]. For patients in the CRT group, an interval of at least 63 days (duration of CRT + 4 weeks to provide the opportunity for tumor regression) and no longer than 182 days (6 months; arbitrary) was required.

Cases were excluded if the date of surgery was not available or if there was presence of distant metastases at time of surgery or missing data regarding distant metastases. The same was true for cases with histopathological tumor type other than adenocarcinoma, mucinous carcinoma, or signet ring cell carcinoma. Other exclusion criteria were missing values for pathological T or N categories and surgical procedures other than a low anterior resection (LAR), Hartmann's procedure, abdominoperineal excision (APE), or intersphincteric resection.

Comorbidity was only registered in the NCR for one specific region in the Netherlands, covering 12% of the population. A subgroup analysis of this data was performed.

Preoperative therapy {#Sec4}
--------------------

The prevailing RC clinical guideline \[[@CR18]\] during the inclusion period recommended preoperative SC-RT for primarily resectable RC (with the exception of cT1N0 tumors) consisting of 5 × 5 Gy followed by surgery within 1 week. Long-course CRT consisting of 45--50 Gy given in 25 fractions of 1.8--2.0 Gy per day with concurrent oral chemotherapy (capecitabine 825--1000 mg/m^2^ twice daily) and followed by surgery within 4--6 weeks was indicated for locally advanced RC (i.e., patients with clinical N2 disease, cT4 tumors, or tumors with suspected involvement of the mesorectal fascia on imaging). Patients treated with surgery only either had cT1N0 disease or were unfit or did not give consent to undergo preoperative treatment.

Statistical analysis {#Sec5}
--------------------

All data was entered in a database and analyzed using IBM SPSS Statistics for Windows, version 22.0, Armonk, NY: IBM Corp. Categorical variables were analyzed using the *χ*^2^ test. Cumulative overall survival was analyzed using the Kaplan-Meier method with log rank test. Univariable and multivariable analyses were performed by entering all applicable clinical and pathological factors in a Cox regression model. A *p* value of \< 0.05 was considered statistically significant whereas a *p* value of \< 0.1 was taken to reflect a trend towards significance.

Results {#Sec6}
=======

Patient selection {#Sec7}
-----------------

The initial search of the NCR database identified 19,737 patients. Figure [1](#Fig1){ref-type="fig"} depicts the selection process, resulting in the inclusion of a total of 11,925 patients (2590 with surgery only, 4534 with SC-RT, and 4801 with CRT).Fig. 1Flow diagram showing the selection process. SC-RT, short-course radiation therapy; CRT, chemoradiation therapy; NOS, not otherwise specified; pT, pathological tumor category; pN, pathological nodal category

Clinicopathological factors {#Sec8}
---------------------------

Table [1](#Tab1){ref-type="table"} provides the clinical and pathological characteristics. Median interval between start of SC-RT and surgery was 8 days (range 0--10), and in the CRT group, the median interval was 100 days (range 63--182). Patients in the surgery-only group were older than those in the SC-RT group, who in turn were older than the CRT-treated patients (age \> 75 years; 40%, 28%, and 13% in the surgery-only, SC-RT, and CRT groups, respectively; *p* \< 0.001). Other factors that were significantly associated with the type of preoperative treatment were cT category, cN category, cTNM stage, type of resection, pT category, pN category, pTNM stage, CRM involvement, histological type, and presence of postoperative chemotherapy. Patients in the CRT group showed ypT0 in 20% of cases and had a reduced rate of (y)pT2 and (y)pT3 tumors compared with those in the surgery-only and SC-RT groups (*p* \< 0.001). A pCR (ypT0N0) occurred in 18% of cases after CRT.Table 1Clinicopathological characteristics of patients treated with surgery only, SC-RT, and CRTTotalSurgery onlySC-RTCRT*p* value*n*%*n*%*n*%*n*%Total11,925259045344801Gender0.092  Male761063.8160862.1289963.9310364.60.485^a^  Female431536.298237.9163536.1169835.4Age at diagnosis\< 0.001  0--443422.9481.9892.02054.3  45--59258321.733412.988619.5136328.4  60--74607851.0117145.2228950.5261854.5  75+292224.5103740.0127028.061512.8Clinical T category\< 0.001  cT13023.11478.01333.8220.5  cT2265626.980043.7141540.14419.8  cT3607061.478342.8193354.7335474.2  cT48528.6995.4521.570115.5  Missing20457611001283Clinical N category\< 0.001  cN0527249.7182480.7259465.985419.4  cN1328431.034815.4119330.3174339.6  cN2204319.3883.91483.8180741.0  Missing1326330599397Clinical TNM stage\< 0.001  Stage I187920.278945.298930.31092.3  Stage II211722.751929.893028.568615.5  Stage III532757.143625.0134141.1360282.2  Missing26028461274482Type of resection\< 0.001  Sphincter saving^b^816168.4215283.1336174.1264855.2  Non-sphincter saving^c^376431.643816.9117325.9215344.8Pathological T category\< 0.001  (y)pT09798.250.2340.794019.6  (y)pT110508.838014.73367.43347.0  (y)pT2407334.289334.5185240.8132827.7  (y)pT3545045.7120646.6223749.3200741.8  (y)pT43733.11064.1751.71924.0Pathological N category\< 0.001  (y)pN0809867.9177568.5295865.2336570.1  (y)pN1263222.156821.9108123.898320.5  (y)pN2119510.02479.549510.94539.4Pathological TNM stage\< 0.001  Stage 08957.540.2250.686618.0  Stage I407034.1105840.8170537.6130727.2  Stage II313326.371327.5122827.1119224.8  Stage III382732.181531.5157634.8143629.9CRM involvement^d^\< 0.020  Absent960592.4198191.6369593.3392992.00.018\*  Present7887.61818.42646.73438.0  Missing1532428575529Histological type0.009  Adenocarcinoma11,04992.7243694.1420892.8440591.80.158\*  Mucinous carcinoma8256.91445.63086.83737.8  Signet ring cell carcinoma510.4100.4180.4230.5Postoperative CTx0.013  No11,17593.7239592.5426394.0451794.1  Yes7506.31957.52716.02845.9*SC-RT* short-course radiation therapy, *CRT* chemoradiation therapy, *CRM* circumferential resection margin, *CTx* chemotherapy^a^SC-RT vs. CRT^b^Includes 6887 patients with low anterior resection, 1186 patients with Hartmann's procedure, and 88 patients with intersphincteric resection^c^Patients with abdominoperineal excision^d^Circumferential resection margin (CRM) involvement was defined as tumor distance to the CRM ≤ 1 mm

A subgroup analysis of cases with available comorbidity data (*n* = 1270) showed a higher rate of comorbidities in the surgery-only group compared with both the SC-RT and CRT groups with ≥ 2 comorbidities in 45%, 35%, and 25% of cases for surgery only, SC-RT, and CRT, respectively (*p* \< 0.001 for surgery only vs. CRT; *p* = 0.006 for surgery only vs. SC-RT; *p* = 0.003 for SC-RT vs. CRT).

Correlation between cTNM and (y)pTNM {#Sec9}
------------------------------------

The data showed substantial discrepancies between clinical and pathological TNM stages (Table [2](#Tab2){ref-type="table"}). Patients with suspected LN on clinical imaging had histopathology showing nodal disease in 57%, 49%, and 35% of cases that were treated with surgery only, SC-RT, and CRT, respectively (*p* \< 0.001). Patients with clinical stage I disease had histopathological nodal involvement in 19%, 24%, and 13% after surgery only, SC-RT, and CRT, respectively (*p* = 0.004). For patients with clinical stage II, this was 26%, 30%, and 15%, respectively (*p* \< 0.001). In the CRT group, there was complete tumor regression in 30%, 19%, and 17% of cases for patients with clinical stage I, II, and III disease, respectively (*p* \< 0.001).Table 2Correlation between clinical and pathological stages*N* = 9323^a^Clinical stageStage IStage IIStage III*n*%*n*%*n*%Surgery onlyPathological stage  Stage 020.310.200.0  Stage I48161.014628.18118.6  Stage II15419.523745.710824.8  Stage III15219.313526.024756.7Total789100.0519100.0436100.0SC-RTPathological stage  Stage 0151.510.140.3  Stage I53554.128630.835926.8  Stage II19920.136839.632023.9  Stage III24024.327529.665849.1Total989100.0930100.01341100.0CRTPathological stage  Stage 03029.712919.360116.9  Stage I4039.620530.789825.3  Stage II1817.823535.282123.1  Stage III1312.99914.8123034.6Total101100.0668100.03550100.0*SC-RT* short-course radiation therapy, *CRT* chemoradiation therapy^a^Cases with missing values for clinical TNM stage were excluded (*n* = 2602)

Survival analysis {#Sec10}
-----------------

Median follow-up was 28 months (range 0--84 months) and 1949 deaths were recorded (16.3%). Cumulative 5-year overall survival was 73% (Table [3](#Tab3){ref-type="table"}). The surgery-only group showed worse overall survival than the SC-RT and CRT groups (64%, 76%, and 74% for surgery only, SC-RT, and CRT, respectively; *p* \< 0.001). However, there was no significant difference between patients treated with SC-RT vs. CRT (*p* = 0.147).Table 3Overall survivalCumulative 5-year overall survival*p* value^a^HR95%CIOverall73%Preoperative therapy\< 0.001  SC-RT76.30.147^†^1.00--  CRT73.51.070.96--1.19  None (surgery only)64.11.731.55--1.94Gender\< 0.001  Male71.31.00--  Female76.00.770.70--0.85Age at diagnosis\< 0.001  0--4485.21.00--  45--5982.01.180.81--1.72  60--7476.91.761.23--2.52  75+56.14.102.87--5.87Clinical T category\< 0.001  cT175.01.00--  cT278.70.990.70--1.39  cT373.11.360.98--1.89  cT461.02.151.51--3.05  Missing71.21.521.09--2.12Clinical N category0.007  cN074.21.00--  cN171.91.100.99--1.23  cN273.60.980.84--1.13  Missing70.61.221.08--1.38Clinical TNM stage\< 0.001  Stage I78.91.00--  Stage II72.01.461.23--1.73  Stage III72.41.381.18--1.61  Missing71.51.511.29--1.77Type of resection0.004  Sphincter saving74.01.00--  Non-sphincter saving71.11.151.05--1.26Pathological T category\< 0.001  pT087.20.730.54--0.99  pT182.01.00--  pT281.01.140.92--1.41  pT365.22.221.81--2.71  pT445.94.503.48--5.82Pathological N category\< 0.001  pN079.21.00--  pN167.21.651.49--1.84  pN247.63.132.79--3.51Pathological stage\< 0.001  Stage 089.20.620.47--0.83  Stage I83.31.00--  Stage II71.51.761.55--2.00  Stage III60.92.612.32--2.93Histological type\< 0.001  Adenocarcinoma73.91.00--  Mucinous carcinoma66.21.411.21--1.63  Signet ring cell carcinoma21.94.172.74--6.35CRM involvement\< 0.001  Absent75.01.00--  Present53.52.241.97--2.56  Missing73.11.171.04--1.32Postoperative CTx0.007  No72.71.00--  Yes77.40.780.65--0.93*SC-RT* short-course radiation therapy, *CRT* chemoradiation therapy, *CRM* circumferential resection margin, *CTx* chemotherapy^a^Log-rank test^†^SC-RT vs. CRT

Clinical stage before neoadjuvant therapy was significantly associated with overall survival, although the hazard ratios are lower than those for pathological stage, and in the study population, the hazard ratios do not consistently increase with clinical stage in contrast to pathological stage, suggesting that the prognostic value of clinical stage is limited (HR 1.00, HR 1.46, and HR 1.38 for clinical TNM stages I, II, and III, respectively; and HR 0.62, HR 1.00, HR 1.76, and HR 2.61 for pathological TNM stages 0, I, II, and III, respectively).

Figure [2a--c](#Fig2){ref-type="fig"} show stage-specific overall survival for patients with surgery only, SC-RT, and CRT. Survival was worst in the surgery-only group (cumulative 5-year survival 77%, 63%, and 52% for pathological stages I, II, and III, respectively; *p* ≤ 0.003 compared with SC-RT and CRT). SC-RT-treated patients with pathological stage I disease had similar overall survival as same-stage patients in the CRT group (cumulative 5-year survival 85% vs. 85%, respectively; *p* = 0.167). After CRT overall survival was comparable in patients with pathological stage I and those who reached a pCR (cumulative 5-year survival 85% vs. 89% respectively; *p* = 0.113). The SC-RT group showed better survival than the CRT group for patients with pathological stage II (cumulative 5-year survival 77% vs. 68% for SC-RT vs. CRT, respectively; *p* = 0.002) and stage III (cumulative 5-year survival 67% vs. 58% for SC-RT vs. CRT, respectively; *p* \< 0.001).Fig. 2Overall survival for patients treated with surgery only, SC-RT, or CRT. **a** Pathological stage I. **b** Pathological stage II. **c** Pathological stage III. SC-RT, short-course radiation therapy; CRT, chemoradiation therapy

The multivariable analysis (Table [4](#Tab4){ref-type="table"}) showed that CRT was independently associated with a higher mortality compared with SC-RT in patients with pathological stage II (HR 1.57 \[95%CI 1.27--1.95\]; *p* \< 0.001) and stage III (HR 1.43 \[95%CI 1.23--1.70\]; *p* \< 0.001), but not in those with stage I (HR 0.99 \[95%CI 0.77--1.27\]; *p* = 0.146). The hazard ratio for patients with surgery only was also increased compared with SC-RT for patients with pathological stage II (HR 1.67 \[95%CI 1.35--2.08\]; *p* \< 0.001) and stage III (HR 1.60 \[95%CI 1.36--1.87\]; *p* \< 0.001), but not stage I (HR 1.25 \[95%CI 0.99--1.59\]; *p* = 0.137).Table 4Multivariable Cox regression analysis for overall survival of patients with pathological TNM stages I--III(y)pTNM stage I(y)pTNM stage II(y)pTNM stage IIIHR95%CI*p* valueHR95%CI*p* valueHR95%CI*p* valuePreoperative therapy0.146\< 0.001\< 0.001  SC-RT1.00--1.00--1.00--  CRT0.990.77--1.271.571.27--1.951.431.23--1.70  None (surgery only)1.250.99--1.591.671.35--2.081.601.36--1.87Gender\< 0.0010.007\< 0.001  Male1.00--1.00--1.00--  Female0.610.49--0.760.780.65--0.940.770.67--0.89Age at diagnosis\< 0.001\< 0.001\< 0.001  0--440.810.24--2.710.800.37--1.740.970.61--1.53  45--591.00--1.00--1.00--  60--742.991.95--4.591.230.94--1.611.351.12--1.63  75+7.885.14--12.102.892.20--3.792.812.29--3.45Type of resection0.1470.0250.002  Sphincter saving1.00--1.00--1.00--  Non-sphincter saving1.170.95--1.451.241.03--1.491.251.09--1.44pT category0.588\< 0.001\< 0.001  pT0--------1.480.75--2.90  pT11.00------1.00--  pT20.930.73--1.20----1.200.75--1.92  pT3----1.00--1.911.22--3.00  pT4----1.791.32--2.423.031.85--4.97pN category\< 0.001  pN1--------1.00--  pN2--------1.881.65--2.15Histological type0.0310.1760.022  Adenocarcinoma1.00--1.00--1.00--  Mucinous carcinoma0.780.48--1.251.150.87--1.521.160.95--1.41  Signet ring cell carcinoma11.291.56--81.702.570.82--8.071.851.13--3.03CRM involvement0.0400.001\< 0.001  Absent1.00--1.00--1.00--  Present1.761.14--2.711.611.25--2.071.541.29--1.84  Missing1.030.80--1.331.230.98--1.541.150.96--1.38Postoperative CTx0.4740.008\< 0.001  No1.00--1.00--1.00--  Yes0.600.15--2.430.300.13--0.730.560.46--0.69*p* pathological, *SC-RT* short-course radiation therapy, *CRT* chemoradiation therapy, *AC* adenocarcinoma, *MC* mucinous carcinoma, *SRCC* signet ring cell carcinoma, *CRM* circumferential resection margin, *CTx* chemotherapy

Discussion {#Sec11}
==========

In this population-based study, using data from the Netherlands Cancer Registry, long-term stage-specific survival data was analyzed from 11,925 RC patients who underwent TME surgery with or without preoperative treatment consisting of either SC-RT or CRT. Patients with downstaging to pathological stage I disease after CRT had an excellent 5-year overall survival which was similar as in SC-RT-treated patients without downstaging (85%). For patients with pathological stages II and III, survival was significantly worse after CRT (68% and 58%) compared with SC-RT (77% and 67%). In addition, clinical staging was a poor predictor of pathological stage based on the large discrepancies between clinical and pathological stages in the surgery-only group.

In the study period, the national clinical guideline \[[@CR18]\] recommended preoperative SC-RT with 5 × 5 Gy and surgery within 1 week for primarily resectable RC (with the exception of cT1N0 tumors) and long-course CRT consisting of 45--50 Gy given in 25 fractions of 1.8--2.0 Gy per day with concurrent oral capecitabine for locally advanced RC (see "[Patients and methods](#Sec2){ref-type="sec"}" section for details). Patients treated with surgery only in this period either had cT1N0 disease or were unfit or did not give consent to undergo the indicated preoperative therapy. Indeed, patients in the surgery-only group were found to be substantially older and had more comorbidity compared with both the SC-RT and CRT groups. These patients were therefore considered to be unsuitable as a control population in the current study.

On the other hand, the comparison of the SC-RT- and CRT-treated patients in this study yields some interesting results. Although some small downstaging effect on T-stage and nodal downstaging have been reported in randomized trials after SC-RT with immediate surgery \[[@CR13], [@CR14]\], the SC-RT-treated patients in the current study all had an overall treatment time not exceeding 10 days, and evidence from a large randomized controlled trial showed that tumor and nodal downstaging do not occur in this short timeframe \[[@CR16]\]. Furthermore, stage-specific 10-year overall survival was shown to be similar in randomized patients with preoperative SC-RT and those with surgery only or surgery with selective postoperative CRT \[[@CR12]--[@CR14]\]. This lack of downstaging and absence of a survival difference suggest that the SC-RT-treated patients in the current study may be regarded best as pTNM rather than ypTNM \[[@CR19]\].

The observed difference in stage-specific survival between patients treated with CRT (substantial downstaging) and SC-RT (no downstaging) was substantial and highly significant, and the effect was independent of several known possible confounders. However, selection bias may be a concern when interpreting these results. The inherently higher levels of treatment-induced toxicity caused by CRT may motivate clinicians to withhold this treatment in elderly patients with comorbidity, whereas the same comorbidity level would not preclude a treatment with much less toxic SC-RT. Unfortunately, comorbidity data was not available in the majority of patients and the results of the multivariable analysis could therefore not be corrected for this confounder. However, the subset analysis of patients with available comorbidity data showed that comorbidity levels were higher in the SC-RT than in the CRT group. As a consequence, the SC-RT group as a whole may be expected to show a bias towards a worse prognosis compared with the CRT group. However, the multivariable analysis showed the direct opposite with a better prognosis in the SC-RT group for patients with stage II and III disease. The observed survival differences may therefore be expected to be even larger if the results could be adjusted for comorbidity.

The introduction of preoperative CRT for RC which has resulted in tumor downstaging in a substantial proportion of patients has not resulted in improved survival compared with selective postoperative CRT \[[@CR20]\]. The stage-specific outcome differences between the groups in this study are therefore not based on a therapeutic effect of the preoperative treatment, but are probably best explained by pathological stage migration. Patients with nodal disease may undergo sterilization of involved LN after CRT resulting in classification as pathological stage I or II disease instead of stage III.

Patients with downstaging to ypTNM stage I reflect a selection of treatment-sensitive tumors. The excellent survival observed in these patients, which is similar to SC-RT-treated pTNM stage I patients, suggests that potential occult disease or metastases also undergo substantial regression in patients with treatment-sensitive tumors. As a consequence, the observed mortality will increase in the ypTNM stage III patients with residual nodal metastases, since this group constitutes a selection of patients with treatment-resistant tumors. Furthermore, mortality can also be expected to increase in the ypTNM stage II group after CRT. This group is enriched with cases that had nodal disease at baseline, with higher risk of occult residual disease but with only intermediate regression to therapy, and this may correspond to intermediate regression of potential occult residual disease as well. This effect, called "the reverse of the Will Rogers phenomenon," has been described before with data from the German CAO/ARO/AIO-94 trial, showing that patients with pathological stage II disease after preoperative CRT had worse overall survival than same-stage patients from the control arm treated with selective postoperative CRT \[[@CR21]\].

A limitation to the current study is that it is not possible to determine the exact rate of stage migration in CRT-treated patients, since clinical staging (especially cN category) is notoriously unreliable \[[@CR22]--[@CR25]\]. Indeed, data from this study showed large discrepancies between clinical and pathological stages in the surgery-only group (no downstaging by definition) with pathologically confirmed LN metastases in only 57% of patients with clinical stage III disease. The differences between clinical and pathological stages in the surgery-only and SC-RT groups and at least a part of the variation observed in the CRT group are therefore probably related to the imprecision of clinical staging and not to actual stage migration. This imprecision is reflected in the relatively limited prognostic value of clinical stage (cTNM) compared with definitive pathological stage ((y)pTNM) observed in this study. Another important restriction is the lack of an adequate pTNM control group, due to the high level of selection bias in patients treated with surgery only.

Furthermore, precise details regarding chemotherapy types and doses received were not available for individual patients, since the national cancer registry does not document this information. It is likely that a part of individual patients in the long-course CRT group received doses that are not equal to the recommended dose due to toxicity issues. In addition, it is possible that some patients in this group received additional chemotherapeutic agents besides capecitabine as part of a clinical trial. Unfortunately, the impact of these minor treatment variations on the results of this study cannot be ascertained.

In conclusion, this population-based study provides evidence that pathological stage I after preoperative CRT for RC is associated with an excellent prognosis, which is comparable with reaching a pCR and similar to same-stage SC-RT-treated patients without tumor regression. In patients with pathological stage II and III disease after CRT, the prognosis is worse than after SC-RT with immediate surgery. These results contain important prognostic information for individual patients and physicians and may have consequences for predictive models. Staging systems, such as TNM, should therefore take stage-specific survival differences between patients treated with different preoperative therapy regimens into account.
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